🔍

Suraksha Diagnostic Limited (SURAKSHA)

₹306.70 -0.31% last close, 16 Oct

📊 NSE: SURAKSHA 🏢 Healthcare 📢 Latest filing: 14 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Suraksha Diagnostic's revenue was ₹87.6 Cr (+20.7% year on year, +7.7% on the previous quarter), and net profit ₹12.8 Cr (+40.0% year on year); the operating margin was 34.7%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹87.6	+20.7%	+7.7%
Operating profit	₹30.4	+28.2%	+24.9%
Net profit	₹12.8	+40.0%	+108.5%
EPS (₹)	2.50	+38.9%	+106.6%
Operating margin	34.7%	—	—

Full quarterly financials → Results calendar →

SURAKSHA delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 45.31% of the SURAKSHA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 52.39%. That is close to its usual level. Turnover was only ₹71 lakh, so a handful of trades can move this figure. Volume was 0.3 times its average, well below normal.

45.31%Delivery, 16 Oct

52.39%Own 20-session average

0.3×Volume vs its average

₹306.70NSE close · -0.31%

Delivery in the last 5 sessions: 40.2% · 41.8% · 48.7% · 55.3% · 45.3%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Suraksha Diagnostic Boards Takes Note of 1-Day NSE Filing Delay; Pays Rs 2,360 Penalty

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 14 Oct 2026, 05:42 PM

Suraksha Diagnostic received a notice from the National Stock Exchange of India (NSE) regarding non-compliance with Regulation 31 of SEBI LODR, due to a 1-day delay in submitting its shareholding pattern for the quarter ended June 30, 2026. A penalty of Rs 2,360 (Rs 2,000 fine plus Rs 360 GST) was levied by the exchange and subsequently paid by the company on September 29, 2026. The Board considered the matter on October 14, 2026, and instructed the secretarial team to tighten internal compliance monitoring mechanisms. The financial impact is entirely immaterial against the company's Rs 325 Cr TTM revenue base.

Non-compliance under Regulation 31 pertained to a 1-day delay in submitting the June 30, 2026 shareholding pattern
Penalty of Rs 2,360 (Rs 2,000 fine + 18% GST of Rs 360) was paid on September 29, 2026
NSE issued a notice on August 31, 2026, advising the company to table the matter at the subsequent Board meeting
Board meeting to note the non-compliance and approve remedial measures was held on October 14, 2026

💡 Track the upcoming Q2 FY27 earnings release and ongoing execution on the planned 12-15 center additions. No operational or governance action is necessitated by this procedural penalty.

Suraksha Diagnostic Concludes 21st AGM; Approves ₹0.50 Per Share Final Dividend

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Sep 2026, 04:13 PM

Suraksha Diagnostic Limited conducted its 21st Annual General Meeting on September 22, 2026, where shareholders approved all tabled resolutions with requisite majority. Approved items include the adoption of FY26 standalone and consolidated financial statements and a final dividend of ₹0.50 per equity share (face value ₹2, or 25%). Additionally, the reappointment of retiring director Mr. Satish Kumar Verma and ratification of cost auditor remuneration were approved.

Held 21st AGM on September 22, 2026, passing all ordinary resolutions with requisite majority
Approved final dividend of ₹0.50 per equity share of face value ₹2 (25%) for FY26
Adopted audited financial statements for the fiscal year ended March 31, 2026
Ratified remuneration for Cost Auditor M/s. S. Chhaparia & Associates for FY27

💡 Track the formal submission of voting results under Regulation 44(3) and the dividend payment timeline.

Suraksha Diagnostic 21st AGM: Approves Rs 0.50 Per Share Final Dividend

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Sep 2026, 06:31 PM

Suraksha Diagnostic Limited concluded its 21st Annual General Meeting on September 22, 2026, where all resolutions were approved by shareholders with the requisite majority. Key business approved included the adoption of FY26 standalone and consolidated financial statements and declaration of a final dividend of Rs 0.50 per equity share (25% on Rs 2 face value). Additionally, shareholders ratified the re-appointment of retiring director Mr. Satish Kumar Verma and approved the remuneration of the cost auditor for FY27. Detailed scrutinizer voting results will be submitted separately under Regulation 44.

Declared final dividend of ₹ 0.50 per equity share of Rs. 2/- each (25%) for FY 2025-26
All resolutions passed by members by requisite majority at the 21st AGM
Ratified remuneration payable to M/s. S. Chhaparia & Associates, Cost Auditor for FY 2026-27
Adopted audited standalone and consolidated financial statements for the year ended March 31, 2026

💡 Track the formal submission of Regulation 44 voting results and the dividend payment timeline.

Suraksha Diagnostic Schedules 21st AGM on Sept 22, Sets Sept 15 Dividend Record Date

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Aug 2026, 08:01 PM

Suraksha Diagnostic Limited announced that its 21st Annual General Meeting (AGM) will be held via Video Conference on September 22, 2026, at 11:30 AM IST. The company has fixed Tuesday, September 15, 2026, as the record date for determining dividend eligibility and cut-off for e-voting. Remote e-voting will run from September 18, 2026 (9:00 AM) to September 21, 2026 (5:00 PM). The filing also intimates dispatch of notices to shareholders whose email IDs are unregistered.

21st Annual General Meeting scheduled for Tuesday, September 22, 2026 at 11:30 AM IST
Record date for dividend entitlement fixed as Tuesday, September 15, 2026
Remote e-voting window open from September 18, 2026 (9:00 AM IST) to September 21, 2026 (5:00 PM IST)
Cut-off date for e-voting eligibility set for September 15, 2026

💡 Shareholders seeking dividend eligibility should ensure shareholding is settled before the record date of September 15, 2026, and update KYC/email details with their Depository Participants.

Suraksha Diagnostic Dispatches FY26 Annual Report; 21st AGM Scheduled for Sept 22, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Aug 2026, 07:58 PM

Suraksha Diagnostic Limited has submitted its Annual Report for FY 2025-26 along with the notice convening its 21st Annual General Meeting (AGM) on September 22, 2026. The report highlights FY26 operations where the company achieved ₹310.41 crore in revenue and ₹31.40 crore in net profit across 68 centres and 193 collection centres. Key revenue drivers remained pathology (49%) and radiology (44%), with 89% coming from B2C channels. This filing is a statutory compliance submission under SEBI Listing Regulations.

21st Annual General Meeting scheduled for September 22, 2026 via electronic mode.
FY26 Revenue from Operations reported at ₹310.41 crore with Profit for the Year at ₹31.40 crore.
Network infrastructure stood at 68 diagnostic centres, 8 laboratories, and 193 collection centres.
Delivered 0.82 crore tests to 0.14 crore patients with an average revenue per patient of ₹2,264.

💡 Track voting outcomes and management commentary from the September 22, 2026 AGM regarding network expansion and the ramp-up of newly added diagnostic centres.

Suraksha Diagnostic Q1 FY27 Transcript: Revenue Up 21% YoY, PAT Jumps 40% to ₹12.8 Cr

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 17 Aug 2026, 04:59 PM

Suraksha Diagnostic released its Q1 FY27 earnings call transcript, reporting a 21% YoY rise in total income to INR 88.7 cr and a 40% YoY jump in PAT to INR 12.8 cr. Network count reached 72 centres, with immature centres (<2 years old) turning EBITDA positive at 6.5% versus -5.5% in the prior quarter. The company is actively expanding beyond West Bengal into Jharkhand and Tripura, with plans to add ~20 labs in FY27. Specialized testing arm Suraksha Genomics grew 136% YoY to INR 1.37 cr, marking five consecutive quarters of sequential growth.

Q1 FY27 total income grew 21% YoY to INR 88.7 cr (INR 887 mn) with EBITDA margin expanding to 36% from 34%.
Net profit surged 40% YoY to INR 12.8 cr (INR 128 mn) with PAT margin reaching 14.7%.
Total centres reached 72 at quarter-end; immature centres turned EBITDA positive at 6.5% margin.
Suraksha Genomics revenue surged 136% YoY to INR 1.37 cr (INR 13.7 mn).
Expansion beyond West Bengal began with a commissioned hub in Jharkhand and an upcoming hub in Tripura.

💡 Track the execution and utilization ramp-up of new centres in Jharkhand and Tripura, alongside monitoring volume growth trends in routine pathology.

Suraksha Diagnostic Releases Q1 FY27 Earnings Call Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Aug 2026, 04:05 PM

Suraksha Diagnostic has published the audio recording of its earnings call held on August 13, 2026, regarding the Q1 FY27 financial results. For the quarter ended June 30, 2026, the company reported revenue of Rs 72.59 Cr and a net profit of Rs 9.18 Cr. The discussion likely covered the company's ongoing expansion strategy of adding 12-15 new centers annually and the performance of its 15 immature centers. Management continues to target a 1-2% annual margin improvement through cost optimization and scaling high-margin segments like Genomics.

Earnings call conducted on August 13, 2026, at 11:30 a.m. IST following Q1 FY27 results.
Q1 FY27 revenue stood at Rs 72.59 Cr, representing approximately 23% of TTM revenue.
Company maintains a target of adding 12-15 new centers in FY26, a ~30% increase in store count.
Management expects EBITDA and PAT margins to increase by 1% to 2% annually through scaling.
Currently, 33% of the company's centers are classified as immature (less than one year old).

💡 Investors should review the recording for management's commentary on the competitive landscape in West Bengal and the execution timeline for the 12-15 new centers planned for the current fiscal year.

Suraksha Diagnostic Releases Q1 FY27 Earnings Call Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Aug 2026, 03:23 PM

Suraksha Diagnostic has disclosed the audio recording of its earnings call held on August 13, 2026, following the release of its Q1 FY27 financial results. The company, which reported a TTM revenue of ₹310 Cr and an operating margin of 30.7%, is currently executing a strategy to add 12-15 new centers annually. This filing is a procedural disclosure under SEBI regulations to provide transparency on management's discussion regarding quarterly performance and business outlook.

Earnings call conducted on August 13, 2026, at 11:30 a.m. IST regarding Q1 FY27 results
Company maintains a target of adding 12-15 new centers annually to expand its Eastern India footprint
Approximately 33% of current centers are classified as immature, including 15 centers less than one year old
TTM revenue stands at ₹310 Cr with a healthy operating profit margin of 30.7%

💡 Investors should review the recording for management's commentary on the integration of the Fetomat acquisition and the timeline for immature centers to reach profitability.

40% PAT Growth in Q1 FY27; Suraksha Diagnostic Reports Margin Expansion to 36%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 07:20 PM

Suraksha Diagnostic reported a strong start to FY27 with total income rising 21% YoY to ₹88.7 Cr. Profitability significantly outperformed revenue growth, with PAT increasing 40% to ₹12.8 Cr and EBITDA margins expanding by 200 bps to 36.0%. Operational efficiency improved as Average Revenue per Patient (ARPP) grew 10.5% to ₹2,321, despite a slight 2.8% dip in tests per patient. The company continued its expansion by adding 1 hub and 3 spoke centers during the quarter.

Profit After Tax (PAT) grew 40% YoY to ₹128 million (₹12.8 Cr) in Q1 FY27.
EBITDA margins improved to 36.0% from 34.0% in the corresponding quarter last year.
Suraksha Genomics segment delivered a robust revenue growth of 136% YoY.
Average Revenue per Patient (ARPP) increased by 10.5% to ₹2,321.
Network expansion continued with the commissioning of 1 hub and 3 spoke centers in Q1 FY27.

💡 Investors should monitor the margin sustainability as the company scales its 15 immature centers and tracks the revenue contribution from the high-margin Genomics segment.

40% PAT Growth in Q1 FY27; Revenue up 21% to ₹87.65 Cr with 36% EBITDA Margin

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 07:14 PM

Suraksha Diagnostic reported a strong start to FY27 with Q1 revenue growing 21% YoY to ₹87.65 Cr and PAT surging 40% to ₹12.85 Cr. Operating margins (EBITDA) expanded to 36.0% from 34.0% YoY, driven by a high B2C revenue mix of 91% and increased revenue per patient of ₹2,321. The company is aggressively expanding its footprint, adding 4 centers in Q1 and entering new markets in Jharkhand and Tripura. A key profitability driver is the maturation of centers; mature centers (>2 years) operate at a 40.9% EBITDA margin compared to just 6.5% for newer centers.

Revenue from operations increased 21% YoY to ₹876.5 Mn, while PAT grew 40% YoY to ₹128.5 Mn.
EBITDA margins reached 36.0%, with mature centers (>2 years) achieving a high margin of 40.9%.
Network expanded to 72 centers as of June 2026, with 9 additional centers (3 hubs, 6 spokes) already launched or planned for FY27.
Suraksha Genomics revenue grew 136% YoY to ₹13.7 Mn, marking five consecutive quarters of sequential growth.
Revenue per patient improved to ₹2,321 in Q1 FY27 from ₹2,101 in Q1 FY26.

💡 Investors should monitor the ramp-up of the 27 'immature' centers (less than 2 years old), as their transition toward the 40.9% margin profile of mature centers is the primary catalyst for earnings growth.

Suraksha Diagnostic Sets Sept 15 Dividend Record Date; Appoints New Group CFO

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 12 Aug 2026, 07:10 PM

Suraksha Diagnostic reported standalone revenue of ₹84.09 Cr for Q1 FY27, representing a sequential growth of 6.7% over the March 2026 quarter. The board has fixed September 15, 2026, as the record date for the FY26 dividend, with the AGM scheduled for September 22. Additionally, Mr. Dinesh Gupta has been appointed as the Group Chief Financial Officer effective August 24, 2026. The company maintained a standalone net profit of ₹12.58 Cr for the quarter ended June 30, 2026.

Standalone Revenue for Q1 FY27 stood at ₹84.09 Cr, up from ₹78.79 Cr in the previous quarter
Standalone Net Profit for the quarter ended June 30, 2026, reported at ₹12.58 Cr
Record date for FY26 dividend entitlement fixed for September 15, 2026
Appointment of Mr. Dinesh Gupta as Group CFO effective August 24, 2026
21st Annual General Meeting (AGM) to be held on September 22, 2026

💡 Investors should track the transition to the new CFO and monitor the upcoming AGM for updates on the company's plan to add 12-15 new centers in FY26.

Suraksha Diagnostic Appoints Dinesh Gupta as CFO; Q1 FY27 PAT Rises 37% to ₹12.58 Cr

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 12 Aug 2026, 06:56 PM

Suraksha Diagnostic reported a strong start to FY27 with Q1 revenue reaching ₹84.08 Cr, a 15.8% increase over the ₹72.59 Cr reported in Q1 FY26. Net profit for the quarter surged 37% YoY to ₹12.58 Cr, driven by improved operational efficiencies. The board has appointed Mr. Dinesh Gupta, a Chartered Accountant with 14 years of experience, as the new Group CFO effective August 24, 2026. Additionally, the company fixed September 15, 2026, as the record date for the FY26 dividend payment.

Q1 FY27 Revenue grew 15.8% YoY to ₹84.08 Cr from ₹72.59 Cr
Net Profit for the quarter increased 37.1% YoY to ₹12.58 Cr
Appointment of Mr. Dinesh Gupta as Group CFO effective August 24, 2026
Record date for FY26 dividend set for September 15, 2026
Profit Before Tax (PBT) stood at ₹16.71 Cr for the quarter ended June 2026

💡 Watch for the new CFO's impact on cost management as the company executes its plan to add 12-15 new centers in FY27. Investors should also note the dividend record date of September 15 for entitlement.

Suraksha Diagnostic Q1 PAT Rises 37% YoY to ₹12.58 Cr; Appoints New Group CFO

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 06:49 PM

Suraksha Diagnostic reported a strong start to FY27 with standalone revenue growing 15.8% YoY to ₹84.09 cr. Net profit saw a significant jump of 37% YoY to ₹12.58 cr, compared to ₹9.18 cr in the year-ago period. The company also announced the appointment of Mr. Dinesh Gupta as Group CFO, effective August 24, 2026, and fixed September 15, 2026, as the record date for the FY26 dividend. These results indicate the company is tracking well against its 15% annual growth guidance.

Standalone Revenue from operations increased 15.8% YoY to ₹84.09 cr in Q1 FY27.
Standalone Net Profit grew 37% YoY to ₹12.58 cr, up from ₹9.18 cr in Q1 FY26.
Earnings Per Share (EPS) improved to ₹2.42 from ₹1.80 in the corresponding quarter last year.
Record date for the FY26 dividend is fixed for September 15, 2026.
Appointment of Mr. Dinesh Gupta as Group CFO, bringing 14 years of finance experience from firms like Genpact and Maersk.

💡 Investors should monitor the execution of the planned 12-15 new center additions for FY26 and the impact of the new CFO on strategic cost management and margin expansion.

Suraksha Diagnostic Q1 Revenue Grows 15.8% YoY to ₹84.09 Cr; Appoints New Group CFO

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 06:46 PM

Suraksha Diagnostic reported a standalone revenue of ₹84.09 Cr for Q1 FY27, a 15.8% increase over the ₹72.59 Cr reported in Q1 FY26. Standalone net profit for the quarter rose to ₹12.58 Cr, compared to ₹9.18 Cr in the year-ago period, reflecting strong bottom-line growth. The board also appointed Mr. Dinesh Gupta as the new Group CFO, effective August 24, 2026, to lead financial strategy. Additionally, the company fixed September 15, 2026, as the record date for the FY26 dividend payment.

Standalone revenue for Q1 FY27 reached ₹84.09 Cr, up 15.8% from ₹72.59 Cr in Q1 FY26.
Standalone net profit increased to ₹12.58 Cr from ₹9.18 Cr in the corresponding quarter of the previous year.
Appointment of Mr. Dinesh Gupta as Group CFO, a seasoned professional with over 14 years of experience.
Record date for the FY26 dividend set for September 15, 2026, with the AGM scheduled for September 22, 2026.
Total standalone expenses for the quarter stood at ₹69.10 Cr, with material costs accounting for ₹11.85 Cr.

💡 Investors should monitor the new CFO's impact on cost management and the execution of the planned 12-15 new center additions for FY26 to sustain this growth momentum.

Suraksha Diagnostic Postpones 21st AGM Scheduled for September 02, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Aug 2026, 01:01 PM

Suraksha Diagnostic Limited has announced the postponement of its 21st Annual General Meeting (AGM), which was originally scheduled for September 02, 2026. The company cited 'unavoidable circumstances' for the delay and stated that a revised date, time, and venue will be communicated in due course. This is a procedural update and does not impact the company's current financial standing, including its TTM revenue of ₹310 Cr or its FY26 expansion target of adding 12-15 new centers.

21st Annual General Meeting (AGM) postponed from the original date of September 02, 2026
Revised date and venue to be decided in accordance with the Companies Act, 2013
Initial intimation regarding the AGM was provided on May 21, 2026
Company maintains its TTM revenue of ₹310 Cr and OPM of 30.7% as per latest filings

💡 Investors should monitor for the revised AGM date and the release of the full Annual Report to review detailed management commentary on the FY26 expansion strategy.

View All SURAKSHA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 15% YoY to INR 251.28 Cr in FY25 from INR 218.52 Cr in FY24. H1 FY26 revenue reached INR 151.43 Cr, an 18.5% increase over H1 FY25 revenue of INR 127.74 Cr, driven by pathology and radiology services.

Geographic Revenue Split

Revenue is highly concentrated in Eastern India, specifically West Bengal and neighboring states, which accounts for nearly 100% of total turnover.

Profitability Margins

EBITDA margin stood at 33.8% in FY25, slightly up from 33.7% in FY24. PAT margin was 12.3% in FY25 (INR 30.98 Cr) compared to 10.6% in FY24 (INR 23.13 Cr). H1 FY26 PAT margin was 11.9% (INR 18.00 Cr).

EBITDA Margin

EBITDA margin was 33.8% in FY25. For H1 FY26, the margin was 33.7%, a decrease from 36.3% in H1 FY25 due to new center expansion costs and a INR 4 Cr revenue impact from floods.

Capital Expenditure

Property, Plant and Equipment (PPE) stood at INR 147.14 Cr in FY25, up from INR 135.05 Cr in FY24. Capital work-in-progress was INR 10.10 Cr as of March 31, 2025.

Credit Rating & Borrowing

The company maintains a healthy financial risk profile with a gearing of 0.03 times and an interest coverage ratio of 9.34 times in fiscal 2025. Total debt was minimal at INR 5.83 Cr.

⚙️ Operational Drivers

Raw Materials

Reagents and consumables represent the primary raw material cost, totaling INR 28.95 Cr in FY25, which is 11.6% of total revenue.

Capacity Expansion

The company is on track to add 12 to 15 centers in FY26, representing a ~30% increase in store count. Currently, 33% of centers are immature, including 15 centers less than one year old.

Raw Material Costs

Cost of materials consumed was INR 28.95 Cr in FY25, up 6.7% from INR 27.13 Cr in FY24. Procurement is managed to support the Hub-and-Spoke model.

Manufacturing Efficiency

Operating leverage is expected to improve as 33% of currently immature centers scale toward optimal utilization.

Logistics & Distribution

Distribution involves sample collection and transport from spokes to hubs; majority of sales are on a cash basis, reducing credit risk.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Growth will be achieved by adding 12-15 new centers annually, scaling 15 existing centers that are less than one year old to reach maturity, and expanding into high-margin segments like Suraksha Genomics and prenatal care via the Fetomat acquisition.

Products & Services

Pathology tests, Radiology services (CT scans, MRI), Genomics, Molecular testing, and Prenatal care.

Brand Portfolio

Suraksha Diagnostic, Suraksha Genomics, Fetomat.

New Products/Services

Launched Suraksha Genomics in Q2 FY26 to provide advanced genetic and molecular testing services.

Market Expansion

Targeting 12-15 new centers in FY26 to deepen dominance in the Eastern India market.

Market Share & Ranking

Established market leader in Eastern India, particularly West Bengal.

Strategic Alliances

Recent acquisition of Fetomat to strengthen the Genomics and prenatal care division.

🌍 External Factors

Industry Trends

The diagnostic industry is shifting toward organized players and specialized testing like Genomics. Suraksha is positioning itself for this shift by launching a dedicated Genomics division.

Competitive Landscape

Intense competition from large pan-India players and several smaller regional players in West Bengal.

Competitive Moat

Moat is built on the Hub-and-Spoke model efficiency and deep regional brand equity in West Bengal, which are sustainable due to high entry barriers in radiology and specialized pathology.

Macro Economic Sensitivity

Sensitive to regional weather patterns (floods) and the timing of festivities which can shift demand by 3-4% in a quarter.

Consumer Behavior

Increasing consumer demand for advanced genetic testing and home collection services.

Geopolitical Risks

Low risk as a domestic service provider, though equipment imports may be subject to trade policies.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Companies Act 2013 and diagnostic standards. Auditors noted that the audit trail (edit log) facility was not enabled throughout FY25, a regulatory non-compliance.

Taxation Policy Impact

Effective tax rate was approximately 23.7% in FY25, with a total tax expense of INR 10.42 Cr on PBT of INR 43.86 Cr.

Legal Contingencies

The company has disclosed the impact of pending litigations in Note 39 of its financial statements; specific INR values for these contingencies were not provided in the snippets.